Abstract

Anti-Müllerian hormone (AMH), or Müllerian-inhibiting substance, is a protein hormone that promotes Müllerian duct regression during male fetal sexual differentiation and regulation of folliculogenesis in women. AMH is a member of the transforming growth factor beta (TGF-β) family, which has evolved to signal through its own dedicated type II receptor, AMH receptor type II (AMHR2). Structures of other TGF-β family members have revealed how ligands infer specificity for their cognate receptors; however, it is unknown how AMH binds AMHR2 at the molecular level. Therefore, in this study, we solved the X-ray crystal structure of AMH bound to the extracellular domain of AMHR2 to a resolution of 2.6Å. The structure reveals that while AMH binds AMHR2 in a similar location to Activin and BMP ligand binding to their type II receptors, differences in both AMH and AMHR2 account for a highly specific interaction. Furthermore, using an AMH responsive cell-based luciferase assay, we show that a conformation in finger 1 of AMHR2 and a salt bridge formed by K534 on AMH and D81/E84 of AMHR2 are key to the AMH/AMHR2 interaction. Overall, our study highlights how AMH engages AMHR2 using a modified paradigm of receptor binding facilitated by modifications to the three-finger toxin fold of AMHR2. Furthermore, understanding these elements contributing to the specificity of binding will help in the design of agonists or antagonists or the selection of antibody therapies.

Highlights

  • Anti-Müllerian hormone (AMH) is a member of the transforming growth factor beta (TGF-β) family, which consists of over 30 unique, secreted ligand dimers, divided into three classes based on sequence identity and receptor utilization: TGF-βs, bone morphogenetic proteins (BMPs), and Activins [7]

  • Crystal Structure of AMH Bound to AMHR2 extracellular domains (ECDs)

  • Insect cell media containing the MPB-AMHR2 was subjected to Ni-affinity chromatography, sizeexclusion chromatography (SEC), tag removal, and a final SEC

Read more

Summary

Introduction

Despite the large number of ligands in the family, there are only seven type I receptors (Alks to Alks7) and five type II receptors (Tβ-R2, BMPR2, ActRIIA, ActRIIB, and AMHR2). This receptor bottleneck means that certain ligands will signal using common receptors or combinations of receptors. AMH is a member of the transforming growth factor beta (TGF-β) family, which consists of over 30 unique, secreted ligand dimers, divided into three classes based on sequence identity and receptor utilization: TGF-βs, bone morphogenetic proteins (BMPs), and Activins [7]. We identify several regions in both AMH and AMHR2 that are responsible for specificity and required for AMH signaling

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call